3-129431556-A-T
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PVS1_ModeratePM2PP5
The NM_001276270.2(MBD4):c.1670T>A(p.Leu557Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000539 in 1,612,848 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001276270.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MBD4 | NM_001276270.2 | c.1670T>A | p.Leu557Ter | stop_gained | 8/8 | ENST00000429544.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MBD4 | ENST00000429544.7 | c.1670T>A | p.Leu557Ter | stop_gained | 8/8 | 1 | NM_001276270.2 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152238Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000319 AC: 8AN: 250988Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135698
GnomAD4 exome AF: 0.0000555 AC: 81AN: 1460610Hom.: 0 Cov.: 29 AF XY: 0.0000427 AC XY: 31AN XY: 726658
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152238Hom.: 0 Cov.: 33 AF XY: 0.0000403 AC XY: 3AN XY: 74378
ClinVar
Submissions by phenotype
Tumor predisposition syndrome 2 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Jul 17, 2023 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with tumour predisposition syndrome 2 (MIM#619975). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0205 - Variant is predicted to result in a truncated protein (premature termination codon is NOT located at least 54 nucleotides upstream of the final exon-exon junction) with less than 1/3 of the protein sequence affected. (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v2 - 8 heterozygotes, 0 homozygotes). (SP) 0601 - Variant is located in the well-established glycosylase domain (PMID: 30049810; PMID: PMID: 32239153). (I) 0704 - Another variant comparable to the one identified in this case has limited previous evidence for pathogenicity. PMID: 30049810 report a male with colonic polyposis and AML homozygous for the MBD4 c.1699_1701del (p.His567del) variant. This variant is predicted to result in an in-frame deletion in the glycosylase domain and glycosylase assays demonstrated that it led to catalytically inactive MBD4. PMID 32239153 identified a germline heterozygous MBD4 c.1706G>A; p.(Trp569*) variant in two unrelated patients with uveal melanoma. Testing on tumour tissue was undertaken in one of these patients and demonstrated somatic loss of the wild-type allele due to monosomy 3. In vitro glycosylase assay confirmed that this variant resulted in catalytically inactive protein. (SP) 0803 - This variant has moderate previous evidence of pathogenicity in at least three unrelated individuals. PMID 35460607 identified this variant compound heterozygous with MBD4 c.939dup (p.Glu314Argfs*13) in a female with colonic polyposis and uveal melanoma. Her deceased sibling with a history of polyposis and AML could not be genotyped. Griffin et al. 2021 (ASH poster abstract) report this variant in trans with MBD4 c.1291C>T (p.Arg431*) in a female wtih AML and colorectal polyposis. This individual's deceased sibling with a history of AML, colorectal cancer and lymphoma could not be genotyped. PMID 30714079 identified this variant as heterozygous in the germline of an individual with uveal melanoma, with hemizygosity for this variant confirmed in the tumour in association with high tumour mutational burden. (SP) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1101 - Very strong and specific phenotype match for this individual. (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 08, 2022 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change creates a premature translational stop signal (p.Leu563*) in the MBD4 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 18 amino acid(s) of the MBD4 protein. This variant is present in population databases (rs200758755, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with clinical features of MBD4-associated neoplasia syndrome (PMID: 30049810, 30714079, 32239153, 35460607). This variant is also known as Leu563Ter. ClinVar contains an entry for this variant (Variation ID: 1700254). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Melanoma, uveal, susceptibility to, 1 Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Aug 08, 2022 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at